Lataa...
Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-junction Adenocarcinoma After Pembrolizumab
Hyperprogression is a pattern of accelerated tumor growth noted uncommonly after the use of immune checkpoint inhibitors in some patients. We present a 56-year-old female with gastroesophageal junction (GEJ) adenocarcinoma who was initially treated with neoadjuvant radiation and chemotherapy with ca...
Tallennettuna:
| Julkaisussa: | Cureus |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Cureus
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6684307/ https://ncbi.nlm.nih.gov/pubmed/31410344 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.4862 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|